secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2022-02-25T23:59:59+00:00
Accession:  0001193125-22-053527
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad targets ~9% core revenue CAGR, 28% adj. EBITDA margin by 2025 at Investor Day
--------------------------------------------------------------------------------

- Core revenue CAGR target of ~9% from 2021 to 2025, excluding COVID-related sales and currency effects.
- Adjusted EBITDA margin target of 28% in 2025, up from 20%+ target set in 2017.
- Previously set 2017 targets of 3-5% revenue growth and 20%+ EBITDA margin were exceeded.
- Growth drivers include ddPCR, single cell analysis, biopharma expansion, and molecular diagnostics.
- Capital allocation strategy includes generating cash flow and pursuing strategic acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000119312522053527/0001193125-22-053527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000119312522053527/d901425d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-053527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer